117719-17-2

Basic information

• Product Name: 2-AMINO-5-BROMO-3-MORPHOLIN-4-YLPYRAZINE
• Synonyms: 5-bromo-3-morpholin-4-ylpyrazin-2-amine;5-BroMo-3-Morpholinopyrazin-2-aMine
• CAS NO: 117719-17-2
• Molecular Formula: C₈H₁₁BrN₄O
• Molecular Weight: 259.11
• Mol File: 117719-17-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 417.029 °C at 760 mmHg
• Flash Point: 206.012 °C
• Appearance: /
• Density: 1.643 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 2-AMINO-5-BROMO-3-MORPHOLIN-4-YLPYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-5-BROMO-3-MORPHOLIN-4-YLPYRAZINE(117719-17-2)
• EPA Substance Registry System: 2-AMINO-5-BROMO-3-MORPHOLIN-4-YLPYRAZINE(117719-17-2)

Safety Data

• Hazardous Substances Data: 117719-17-2(Hazardous Substances Data)

Usage

General Description

2-AMINO-5-BROMO-3-MORPHOLIN-4-YLPYRAZINE is a chemical compound with the molecular formula C8H10BrN5O. It is a pyrazine derivative containing a bromine atom and a morpholine ring. 2-AMINO-5-BROMO-3-MORPHOLIN-4-YLPYRAZINE has potential applications in the pharmaceutical industry, particularly in the development of new drugs and therapeutic agents. It may also be used as a research tool in chemical and biological studies. The specific properties and potential uses of 2-AMINO-5-BROMO-3-MORPHOLIN-4-YLPYRAZINE are still being explored, and it has not yet been widely commercialized.

InChI:InChI=1/C8H11BrN4O/c9-6-5-11-7(10)8(12-6)13-1-3-14-4-2-13/h5H,1-4H2,(H2,10,11)

Upstream product

• 110-91-8 morpholine 
• 24241-18-7 2-amino-3,5-dibromopyrazine 

Downstream Products

• 1280205-01-7 methyl 3-(3-(2,4,4-trimethylpentan-2-ylamino)-6-(3-methoxyphenyl)-8-morpholinoimidazo[1,2-a]pyrazin-2-yl)propanoate 
• 1280204-99-0 methyl 3-(3-amino-6-(3-methoxyphenyl)-8-morpholino-imidazo[1,2-a]pyrazin-2-yl)propanoate 
• 1280203-78-2 C₂₀H₂₁N₅O₃ 
• 1280205-09-5 methyl 3-((methoxycarbonyl)methyl)-6-(3-methoxyphenyl)-8-morpholinoimidazo[1,2-a]pyrazine-2-carboxylate 
• 1280205-07-3 2-(2-(hydroxymethyl)-6-(3-methoxyphenyl)-8-morpholino-imidazo[1,2-a]pyrazin-3-yl)ethanol 
• 1280203-79-3 C₂₀H₂₃N₅O₂ 
• 1280203-83-9 C₁₉H₁₉N₅O₃ 
• 1280204-16-1 C₂₃H₂₃FN₈O₃S 
• 1280204-63-8 C₂₆H₃₀N₁₀O₂ 
• 1280201-36-6 3-(3-hydroxy-phenyl)-1-morpholin-4-yl-7,8-dihydro-5H-2,4a,6,9-tetraaza-fluorene-6-carboxylic acid ethyl ester 
• 1280202-79-0 C₂₆H₃₀N₁₀O₂ 
• 1280202-89-2 C₂₄H₂₄FN₉O₂ 
• 1280202-37-0 C₂₃H₂₄N₈O₃S 
• 1280202-35-8 C₂₄H₂₃FN₈O₂ 

Relevant articles and documents

Imidazo[1,2-a]pyrazines as novel PI3K inhibitors

Phosphoinositide-3-kinase (PI3K) is an important target for cancer therapeutics due to the deregulation of its signaling pathway in a wide variety of human cancers. We describe herein a novel series of imidazo[1,2-a]pyrazines as PI3K inhibitors.

Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing

The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgd1α) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.

Synthesis and biological evaluation of novel 8-morpholinoimidazo[1,2-a]pyrazine derivatives bearing phenylpyridine/phenylpyrimidine-carboxamides

Herein we designed and synthesized three series of novel 8-morpholinoimidazo[1,2-a] pyrazine derivatives bearing phenylpyridine/phenylpyrimidine-carboxamides (compounds 12a-g, 13a-g and 14a-g). All the compounds were evaluated for their IC50 values against three cancer cell lines (A549, PC-3 and MCF-7). Most of the target compounds exhibited moderate cytotoxicity against the three cancer cell lines. Two selected compounds 14b, 14c were further tested for their activity against PI3Kα kinase, and the results indicated that compound 14c showed inhibitory activity against PI3Kα kinase with an IC50 value of 1.25 μM. Structure-activity relationships (SARs) and pharmacological results indicated that the replacement of the thiopyranopyrimidine with an imidazopyrazine was beneficial for the activity and the position of aryl group has a significant influence to the activity of these compounds. The compounds 13a-g in which an aryl group substituted at the C-4 position of the pyridine ring were more active than 12a-g substituted at the C-5 position. Moreover, the cytotoxicity of compounds 14a-g bearing phenylpyrimidine-carboxamides was better than that of the compounds 12a-g, 13a-g bearing phenylpyridine-carboxamides. Furthermore, the substituents on the benzene ring also had a significant impact on the cytotoxicity and the pharmacological results showed that electron donating groups were beneficial to the cytotoxicity.